ClinicalTrials.gov
public full text
Public Domain
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma#844069
- CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma#1032395
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas#349945
- Older patients with LBCL show comparable outcomes to younger patients and product-specific profiles in CAR-T therapy#1081244
- Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma#140978
Record · ID 1124807
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive